Alumis (ALMS) stock has been in focus after the company reported positive topline results from the ONWARD3 extension study of envudeucitinib for moderate to severe plaque psoriasis, alongside recent second quarter earnings that showed continued net losses.

The ONWARD3 data and upcoming New Drug Application appear to be the key drivers behind Alumis’s recent move, with the share price showing a 5.73% 1-day share price return, a softer 30-day share price return of 13.68% decline, and a very large 1-year total shareholder return of 399.38%. Taken together, these figures suggest strong long-term momentum despite some recent consolidation.

If you are looking beyond Alumis and want to see how other healthcare companies using AI are shaping up, this is a good moment to scan 41 healthcare AI stocks.

Given Alumis stock is trading at about a one-third discount to the average analyst price target after a very large 1-year return, the key question now is where fair value lies between the current price and that range of estimates.

Preferred Price-to-Book Multiple of 6.9x: Is it justified?

Alumis currently trades on a price-to-book, or P/B, ratio of 6.9x, which sits below the peer average of 8.8x but above the broader US Pharmaceuticals sector average of 2.7x. With the last close at $24.17 and the stock at a sizeable discount to the average analyst price target, this P/B context gives another angle on how the market is pricing the company.

The P/B ratio compares a company’s market value to its book value, essentially what its net assets are worth on the balance sheet. For a clinical stage biopharmaceutical company like Alumis that is still reporting losses, P/B is often used in place of earnings based metrics, since profitability is not yet available to anchor a P/E ratio.

On one side, the 6.9x P/B is lower than the 8.8x peer average described in the data, which points to Alumis trading at a discount relative to a closer comparison group. On the other side, that same 6.9x is much higher than the 2.7x average for the wider US Pharmaceuticals industry, which suggests the market is applying a premium compared to the broader sector and may be pricing in stronger expectations than for many other companies.

Result: Price-to-book of 6.9x (ABOUT RIGHT)

However, investors still need to watch for clinical or regulatory setbacks around envudeucitinib, as well as the ongoing net losses of $438.957 million weighing on Alumis.

Next Steps

With Alumis showing both strong enthusiasm and clear concerns in the data, it makes sense to look closely and decide quickly where you stand. A good place to start is by weighing its upside potential against the key issues flagged in the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Alumis?

If Alumis has your attention, do not stop here. Use this momentum to widen your watchlist with fresh opportunities built from consistent data and clear criteria.

• Spot potential value opportunities early by reviewing companies highlighted in the 48 high quality undervalued stocks that currently look mispriced relative to their fundamentals.
• Strengthen your focus on resilience by checking out the solid balance sheet and fundamentals stocks screener (50 results) to see which companies pair financial stability with underlying business quality.
• Reduce avoidable surprises by scanning the 76 resilient stocks with low risk scores that screens for companies with lower overall risk profiles based on key financial indicators.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.